Skip to content
Biodatica
Start free

Investigator

Jun Yang

ST. JUDE CHILDREN'S RESEARCH HOSPITAL · funded by NCI, NEI, NIAID

Companies
1

Resolved onto their grants.

Grants
10

Federal awards on file.

Non-dilutive funding
$5.2M

Summed across those awards.

First award
Apr 1, 2005

Latest Mar 13, 2026.

Companies from this work

Pre-ticker companies the crosswalk resolved onto a grant filed under this investigator. Momentum shows for the therapeutic areas your seat covers; open a dossier for the full crosswalk.

Grant record

Federal awards filed under this investigator name, newest first. Each links to the public record where the awarding agency publishes one.

  1. R01

    Transcriptional suppression of innate immunity by chimeric transcription factors

    $617k

    Mar 13, 2026NCIST. JUDE CHILDREN'S RESEARCH HOSPITALNIH RePORTER · 11297270 (opens the source filing in a new tab)

  2. R01

    Targeting splicing vulnerability of neuroblastoma

    $767k

    Aug 1, 2025NCIST. JUDE CHILDREN'S RESEARCH HOSPITALNIH RePORTER · 11207884 (opens the source filing in a new tab)

  3. R01

    The role of centriole linkage in retinal degeneration and hearing loss

    $462k

    Mar 1, 2025NEIUTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAHNIH RePORTER · 11025390 (opens the source filing in a new tab)

  4. R01

    The role of centriole linkage in retinal degeneration and hearing loss

    $462k

    Mar 1, 2025NEIUTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAHNIH RePORTER · 11290833 (opens the source filing in a new tab)

  5. R01

    Targetable epigenetic modifiers that promote neuroblastoma malignancy and plasticity

    $718k

    Jan 15, 2025NCIST. JUDE CHILDREN'S RESEARCH HOSPITALNIH RePORTER · 11050940 (opens the source filing in a new tab)

  6. R01

    Targetable epigenetic modifiers that promote neuroblastoma malignancy and plasticity

    $697k

    Jan 15, 2025NCIST. JUDE CHILDREN'S RESEARCH HOSPITALNIH RePORTER · 11258053 (opens the source filing in a new tab)

  7. R21

    Silencer-enhancer transition dysregulates interleukin-6 in mucosal epithelial cell plasticity

    $200k

    Jul 12, 2024NIAIDUNIVERSITY OF TEXAS MED BR GALVESTONNIH RePORTER · 11137707 (opens the source filing in a new tab)

  8. R01

    Disease mechanism of Usher syndrome 2

    $399k

    Sep 1, 2023NEIUTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAHNIH RePORTER · 11142660 (opens the source filing in a new tab)

  9. R01

    EXPLORE AND TARGET THE EPIGENETIC VULNERABILITY OF PAX3-FOXO1-DRIVEN RHABDOMYOSARCOMA

    $691k

    Jul 1, 2022NCIST. JUDE CHILDREN'S RESEARCH HOSPITALNIH RePORTER · 11122258 (opens the source filing in a new tab)

  10. P30

    Biochemistry/Cell Biology Core

    $153k

    Apr 1, 2005NEIUTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAHNIH RePORTER · 11198856 (opens the source filing in a new tab)

This page aggregates public U.S. federal grant records filed under one investigator name and the companies Biodatica has resolved onto them. Names are shown as the awarding agency filed them; grant awards are non-dilutive federal funding, not equity or valuation. Distinct people who file under the same name would appear together here. It is informational only and not investment advice. Methodology · Data sources